The British Association of Dermatologists and British Geriatrics Society recommend routine screening for frailty for all patients aged ≥ 65 years being considered for management of skin cancer using a validated tool such as the Rockwood Clinical Frailty Scale.
Lay Summary: Nodular prurigo (NP) is a chronic skin condition. Lesions can be either single or widespread on the body. Thus, it can have a negative impact on a person’s quality of life. The exact cause of NP is unknown, as several mechanisms play a role. These mechanisms sometimes overlap between physical and brain–behavioural elements. Dermatologists diagnose NP based on a history of long-lasting itching and scratching. A Guideline Development Group met to produce a new guideline for treating people with NP. The group included consultant dermatologists, a psychotherapist, dermatology trainees, a general practitioner and people with lived experience of NP. The group identified and reviewed the current literature on treating NP. They discussed the findings at length before producing a set of recommendations. The guideline will provide up-to-date management guidance for healthcare practitioners. Initial steps included taking a full history and examination of patients. This included causes of itch, patient education and reversing the itch–scratch habit. The first treatment option is usually topical therapy (applied to the skin). If this fails, other options include phototherapy and oral medications. Further treatments include nonsedating antihistamines and low-dose antidepressants. Steroid injections or cryotherapy (freezing with liquid nitrogen) are options for single lesions. The guideline provides recommendations for treating people with NP. It also includes recommendations for future research and audit points for hospitals. A patient information leaflet is available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/nodular-prurigo).
28 January 2026 in Clinical and Experimental Dermatology
We conducted a retrospective cohort study across four UK centres to establish whether therapeutic drug monitoring and dose escalation of adalimumab up to 80 mg weekly improved patient outcomes. This study represents one of the largest cohorts examining therapeutic drug monitoring and high-dose adalimumab in patients with hidradenitis suppurativa. Unlike previous studies, we did not observe significant mean improvements across standardized outcome measures, despite over 50% of patients being assessed by their clinicians as showing overall improvement.